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Accelerated access to new drugs and technologies
UK government’s proposed scheme is unlikely to improve patient outcomes
Huseyin Naci assistant professor of health policy, Elias Mossialos Brian Abel-Smith professor of
health policy
London School of Economics and Political Science, London, UK
In a new report,1 the UK government has endorsed the
recommendations of last year’s accelerated access review2 and
announced its plans to introduce a faster route to market for
“strategically important and transformative” medicines, devices,
diagnostics, and digital technologies. With the accelerated access
pathway, scheduled for April 2018, the government has made
an unprecedented pledge to “bring forward by up to four years
patient access to selected, highly beneficial and affordable
innovations.”
The proposed pathway adds to an already crowded landscape
of regulatory initiatives aiming to expedite the approval,
reimbursement, and adoption of promising new technologies
in the NHS. The recently reformed Cancer Drugs Fund is one
example,3 along with the early access to medicines scheme
allowing patients to use drugs before formal regulatory approval4
and the National Institute for Health and Care Excellence’s “fast
track” appraisal process that guarantees expedited funding for
highly cost effective technologies.5
So, what is new about the new pathway? A core objective is to
foster technological advances for previously unmet needs. A
newly established collaborative with patient, industry, and
clinician representatives will select the most suitable products
for the pathway. How the collaborative will define unmet needs
is unclear. Enhanced NHS horizon scanning is mentioned, but
this method identifies only research and development activities
that are planned or under way. Without rigorous assessment of
population level needs, the collaborative may end up reviewing
and selecting the best technologies among those available rather
than those most needed.
Questionable benefits
What can patients and the public expect from the new pathway?
One of the key recommendations is to identify “breakthrough”
technologies and expedite their development, approval, and
adoption in the NHS. This resembles similar initiatives by the
US Food and Drug Administration (FDA) to expedite marketing
approval for medicines that treat rare, serious, or life threatening
conditions. Research to date shows that most products with
expedited approval do not offer a step change in patient
outcomes.6 7
The US experience also highlights two other important issues
that the UK government should consider before launching the
new pathway. Firstly, the process relies on early studies to select
promising technologies. Early studies tend to exaggerate
benefits, which then decline as longer term evidence
accumulates.8 9 Short term surrogate measures such as
radiological or laboratory markers do not always materialise
into long term clinical benefits such as improved symptoms or
survival unless the relation between surrogate and clinical
outcome has been validated rigorously.10 In addition, expedited
drugs are more likely to have safety problems later on than drugs
approved through regular pathways.11 12
Sponsors of technologies selected on the basis of incomplete
data should be required to conduct post-marketing studies to
establish meaningful benefit and safety. However, these studies
are often delayed or terminated and may not confirm the promise
of earlier studies.6 13 Clear incentives to continue meaningful
research, coupled with effective oversight and enforcement,
should be a priority.
Balancing act
Secondly, the government’s ambition to achieve cost neutrality
overlooks the considerable tension between faster access and
affordability. Sponsors pursuing expedited approvals often set
high prices for their “breakthrough” products, and some of these
products are cost effective despite the high price tag.14 Therefore,
faster access to new drugs and technologies is likely to
escalate—not control—healthcare spending.
Although the government has committed to offset extra costs
by identifying and expediting other products that deliver savings,
innovations that save money are exceedingly rare.15 Even if such
technologies existed, it’s unclear how they would be identified
early in the regulatory process with limited data. Without
additional funding or an effective parallel NHS-wide strategy
to stop funding ineffective interventions, the feasibility of the
fast track proposals is questionable.
What does the government want to achieve with accelerated
access? It is a bold attempt to strike a balance between health
and industrial policy. The UK is one of the few countries with
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a strong life sciences industry. Understandably, it is eager to
attract international investment and make the NHS an attractive
place for a global industry’s research and development activities.
Nonetheless, the proposal says too little on expected benefits
for patients and wider society. Instead, several concrete pledges
are made to industry, including a promise to establish a new
commercial unit within the NHS to “immediately streamline
the pathway for access discussions” and pave the way for
“flexible and confidential commercial arrangements.” Why?
Because innovators want it, according to the report. Furthermore,
the government’s preliminary criteria for judging the success
of the pathway mention indicators such as “level of industry
interest” and “speed of product progression through the
accelerated access pathway” ahead of “improved health and
quality outcomes.”
The UK government has joined the global race to provide faster
market access to new drugs and technologies.16 If the goal is to
improve health outcomes, we should focus on better not faster
approvals17 and send a clear message to industry about the needs
and priorities of the NHS and all who use it.
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